| Jessica Marie Roestenburg, OTR/L | |
|
3741 W 12600 S, Riverton, UT 84065 | |
| (801) 285-4000 | |
| Not Available |
| Full Name | Jessica Marie Roestenburg |
|---|---|
| Gender | Female |
| Speciality | Occupational Therapist |
| Location | 3741 W 12600 S, Riverton, Utah |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1245885664 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225X00000X | Occupational Therapist | 11202028-4201 (Utah) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Jessica Marie Roestenburg, OTR/L 3741 W 12600 S, Riverton, UT 84065-7215 Ph: () - | Jessica Marie Roestenburg, OTR/L 3741 W 12600 S, Riverton, UT 84065 Ph: (801) 285-4000 |
News Archive
QRxPharma announced today the successful outcome of a Phase 1 trial for MoxDuo CR, a controlled-release (CR) Dual-Opioid(TM) designed to provide 12 hours of pain relief in patients suffering from moderate to severe chronic pain (including cancer, lower back, osteoarthritis and neuropathic). The purpose of the trial was to determine which of the various experimental formulations provided the optimum duration of drug levels in the blood.
In an advance toward providing mosquito-plagued people, pets and livestock with an invisibility cloak against these blood-sucking insects, scientists today described discovery of substances that occur naturally on human skin and block mosquitoes' ability to smell and target their victims.
Dogs that undergo curative surgery for transitional cell carcinoma before initiating a combination of doxorubicin and piroxicam therapy have significantly longer median overall survival than their counterparts not pretreated surgically, report researchers.
Rockwell Medical, a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease, chronic kidney disease, and iron deficiency anemia, announced today that it has successfully completed an End of Phase II meeting with the U.S. Food and Drug Administration regarding the Company's lead drug candidate Soluble Ferric Pyrophosphate, a novel continuous iron-replacement therapy designed to treat iron deficiency anemia in hemodialysis patients.
› Verified 9 days ago
Cambry Kaylor, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 3741 W 12600 S, Riverton, UT 84065 Phone: 801-571-3081 | |
Brynnan Halsey, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 3741 W 12600 S Ste 100, Riverton, UT 84065 Phone: 801-571-3081 | |
Andie Marie Stevens, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 3773 W 12600 S, Riverton, UT 84065 Phone: 801-285-1700 | |
Brooklyn Kaye Simon, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 3741 W 12600 S Ste 100, Riverton, UT 84065 Phone: 801-571-3081 | |
Nellie Bubb, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 3723 W 12600 S, Riverton, UT 84065 Phone: 833-577-3422 | |
Savannah Hall, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 3741 W 12600 S Ste 100, Riverton, UT 84065 Phone: 770-822-9115 |